Total Payments
$3.4M
2024 Payments
$177,388
Companies
53
Transactions
2,909
Medicare Patients
3,114
Medicare Billing
$2.3M
Payment Breakdown by Category
Other$1.8M (52.1%)
Research$1.2M (34.8%)
Consulting$311,573 (9.1%)
Travel$89,459 (2.6%)
Food & Beverage$45,553 (1.3%)
Education$946.34 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 608 | 50.0% |
| Unspecified | $1.2M | 112 | 34.8% |
| Consulting Fee | $311,573 | 108 | 9.1% |
| Travel and Lodging | $89,459 | 482 | 2.6% |
| Food and Beverage | $45,553 | 1,529 | 1.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $41,600 | 15 | 1.2% |
| Honoraria | $29,580 | 11 | 0.9% |
| Education | $946.34 | 42 | 0.0% |
| Grant | $87.00 | 2 | 0.0% |
Payments by Type
General
$2.2M
2,797 transactions
Research
$1.2M
112 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| LEO Pharma Inc. | $767,524 | 118 | $0 (2024) |
| ABBVIE INC. | $545,780 | 550 | $0 (2024) |
| Lilly USA, LLC | $408,047 | 429 | $0 (2024) |
| Bausch Health US, LLC | $213,375 | 6 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $187,194 | 233 | $0 (2024) |
| Eli Lilly and Company | $179,408 | 56 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $170,391 | 136 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $149,492 | 146 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $144,333 | 118 | $0 (2024) |
| Incyte Corporation | $122,963 | 91 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $177,388 | 290 | E.R. Squibb & Sons, L.L.C. ($56,100) |
| 2023 | $617,833 | 353 | LEO Pharma Inc. ($386,348) |
| 2022 | $330,857 | 403 | ABBVIE INC. ($113,024) |
| 2021 | $299,220 | 297 | Lilly USA, LLC ($62,265) |
| 2020 | $284,849 | 180 | Bausch Health US, LLC ($86,063) |
| 2019 | $551,872 | 366 | LEO Pharma Inc. ($126,732) |
| 2018 | $547,145 | 477 | Lilly USA, LLC ($87,207) |
| 2017 | $604,403 | 543 | LEO Pharma Inc. ($136,814) |
All Payment Transactions
2,909 individual payment records from CMS Open Payments — Page 1 of 117
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $11.25 | General |
| Category: IMMUNOLOGY | ||||||
| 12/23/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $53.60 | General |
| Category: IMMUNOLOGY | ||||||
| 12/23/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: Dermatology | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: DERMATOLOGY | ||||||
| 12/17/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $1.09 | General |
| Category: Immunology | ||||||
| 12/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Immunology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $12.52 | General |
| Category: Immunology | ||||||
| 12/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $7.97 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: DERMATOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $55.88 | General |
| Category: Immunology | ||||||
| 12/10/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: DERMATOLOGY | ||||||
| 12/10/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: DERMATOLOGY | ||||||
| 12/06/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: Immunology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 12/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $53.60 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $17.27 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A SINGLE-CENTER, OPEN-LABEL STUDY TO EVALUATE TRALOKINUMAB IN ATOPIC DEMATITIS SUBJECTS WHO EXPERIENCED INADEQUATE RESPONSE ON DUPILUMAB | LEO Pharma Inc. | $386,227 | 3 |
| OPEN LABEL, OBSERVATIONAL STUDY, EVALUATING ENSTILAR QD IN PSORIASIS PATIENTS BEING TREATED WITH BIOLOGIC AGENTS | LEO Pharma Inc. | $132,027 | 4 |
| OPEN LABEL, OBSERVATIONAL STUDY, EVALUATING ENSTILAR CALCIPOTRIENEBETAMETHASONE DIPROPIONATE FOAM, 0.0050.064 QD IN PSORIASIS PATIENTS BEING TREATED WITH ETANERCEPT OR ADALIMUMAB | LEO Pharma Inc. | $126,650 | 2 |
| 2019-4723 Bagel | Bausch Health US, LLC | $86,063 | 2 |
| OPEN LABEL, OBSERVATIONAL STUDY, EVALUATING ENSTILAR (CALCIPOTRIENE/BETAMETHASONE DIPROPIONATE) FOAM, 0.005%/0.064% QD IN PSORIASIS PATIENTS BEING TREATED WITH ETANERCEPT OR ADALIMUMAB | LEO Pharma Inc. | $70,000 | 2 |
| 2019-4723-Bagel | Bausch Health US, LLC | $63,656 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $60,910 | 2 |
| 2019-4723 - Bagel | Bausch Health US, LLC | $43,031 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO- CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE-TO- SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $32,240 | 4 |
| A SINGLE-CENTER OPEN-LABEL STUDY TO EVALUATE TRALOKINUMAB IN ATOPIC DEMATITIS SUBJECTS WHO EXPERIENCED INADEQUATE RESPONSE ON DUPILUMAB | LEO Pharma Inc. | $26,873 | 1 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $23,062 | 2 |
| MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $20,750 | 3 |
| 2019-4723- Bagel | Bausch Health US, LLC | $20,625 | 1 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $17,921 | 22 |
| CC-10004-PSOR-012 | Celgene Corporation | $14,130 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $13,262 | 7 |
| A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | Eli Lilly and Company | $8,837 | 3 |
| A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD | Eli Lilly and Company | $7,921 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $5,183 | 7 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $3,705 | 7 |
| Pruritus Mechanism | GENZYME CORPORATION | $2,750 | 7 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,663 | 2 |
| A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $2,591 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,310 | 6 |
| A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis | UCB, Inc. | $2,300 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAINTENANCE TREATMENT PERIOD TO EVALUATE THE EFFICACY | UCB, Inc. | $2,300 | 1 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,034 | 5 |
| A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE EFFICACY AS ASSESSED BY PSORIASIS AREA AND SEVERITY INDEX AT 16 WEEKS OF TREATMENT COMPARED TO USTEKINUMAB AND TO ASSESS LONG TERM SAFETY TOLERABILITY AND EFFICACY IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Novartis Pharmaceuticals Corporation | $1,928 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $1,815 | 1 |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis (CC-10004-PSOR-008) | Celgene Corporation | $1,144 | 1 |
| CC-10004-PSOR-012 - A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate Plaque Psoriasis | Celgene Corporation | $967.00 | 1 |
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $629.00 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $472.19 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIA | UCB, Inc. | $420.00 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS W | UCB, Inc. | $420.00 | 1 |
| AN EXPLORATORY RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY TO EXPLORE THE MODULATION OF INFLAMMATION IN THE SKIN CUTANEOUS ADIPOSE TISSUE AND BLOOD ENDOTHELIAL CELL INTERFACE BY COSENTYX SECUKINUMAB VERSUS PLACEBO IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS ADIPSO | Novartis Pharmaceuticals Corporation | $259.00 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
| M15-997 | AbbVie, Inc. | $24.24 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 816 | 9,679 | $2.3M | $989,759 |
| 2022 | 19 | 824 | 9,121 | $1.8M | $941,329 |
| 2021 | 17 | 876 | 2,518 | $393,052 | $219,855 |
| 2020 | 13 | 598 | 2,125 | $312,188 | $177,952 |
Total Patients
3,114
Total Services
23,443
Medicare Billing
$2.3M
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2023 | 26 | 7,700 | $1.9M | $843,856 | 43.7% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2023 | 35 | 772 | $125,100 | $79,896 | 63.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 116 | 210 | $50,909 | $20,316 | 39.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 138 | 165 | $30,058 | $11,339 | 37.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 73 | 81 | $24,164 | $6,016 | 24.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 82 | 96 | $11,745 | $4,370 | 37.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 39 | 44 | $13,238 | $4,217 | 31.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 66 | 87 | $17,024 | $4,075 | 23.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $9,071 | $3,695 | 40.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 44 | 44 | $9,801 | $3,317 | 33.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 18 | 20 | $5,754 | $1,836 | 31.9% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 12 | 13 | $4,877 | $1,697 | 34.8% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 23 | 23 | $3,350 | $1,272 | 38.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 42 | 235 | $6,407 | $1,263 | 19.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 37 | 106 | $6,906 | $1,144 | 16.6% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 12 | 18 | $3,024 | $731.16 | 24.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 13 | 17 | $2,340 | $702.71 | 30.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 12 | 20 | $200.00 | $16.39 | 8.2% |
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2022 | 23 | 6,900 | $1.4M | $747,254 | 52.6% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2022 | 39 | 1,045 | $156,750 | $113,182 | 72.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 104 | 184 | $46,504 | $18,380 | 39.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 149 | 177 | $31,772 | $12,095 | 38.1% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2022 | 15 | 22 | $15,524 | $6,827 | 44.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 73 | 80 | $23,524 | $6,305 | 26.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 44 | 44 | $14,463 | $5,464 | 37.8% |
About Dr. Jerry Bagel, MD
Dr. Jerry Bagel, MD is a Dermatology healthcare provider based in East Windsor, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992772156.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jerry Bagel, MD has received a total of $3.4M in payments from pharmaceutical and medical device companies, with $177,388 received in 2024. These payments were reported across 2,909 transactions from 53 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.7M).
As a Medicare-enrolled provider, Bagel has provided services to 3,114 Medicare beneficiaries, totaling 23,443 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location East Windsor, NJ
- Active Since 03/07/2006
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1992772156
Products in Payments
- TALTZ (Drug) $438,429
- ADBRY (Biological) $413,525
- ENSTILAR (Drug) $348,692
- DUOBRII (Drug) $213,748
- Humira (Biological) $193,221
- COSENTYX (Biological) $179,039
- SKYRIZI (Biological) $169,590
- DUPIXENT DUPILUMAB INJECTION (Biological) $122,820
- RINVOQ (Biological) $120,957
- OPZELURA (Drug) $120,163
- Sotyktu (Drug) $103,824
- TREMFYA (Drug) $103,345
- Tremfya (Drug) $87,283
- DUPIXENT (Biological) $76,047
- Otezla (Drug) $70,388
- SILIQ (Drug) $68,291
- ATOPIC DERMATITIS - DISEASE (Drug) $56,673
- STELARA (Biological) $43,586
- DUPIXENT (Drug) $31,820
- Ilumya (Biological) $29,125
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in East Windsor
Dr. Brian Keegan, M.d., Ph. D, M.D., PH. D
Dermatology — Payments: $1.9M
Dermatology $1.9M
Mr. David Nieves, Md, MD
Dermatology — Payments: $99,821
Dermatology $99,821
Dr. Wendy Myers, M.d, M.D
Dermatology — Payments: $9,942
Dermatology $9,942
Mrs. Judit Stenn, Md, MD
Dermatology — Payments: $236.33
Dermatology $236.33